Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. - Test2 - elhamkhani - TriplyDB

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

http://www.wikidata.org/entity/Q34579373

about

Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry.The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype Triple-negative breast cancer: role of specific chemotherapy agents The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.Molecular Heterogeneity of Triple Negative Breast Cancer.Subtyping of triple-negative breast cancer: implications for therapy Standard of care and promising new agents for triple negative metastatic breast cancer Regulators of homologous recombination repair as novel targets for cancer treatment.Drug therapy for hereditary cancers Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature.Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.Regulation of therapeutic resistance in cancers by receptor tyrosine kinases.Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.BRCA1/2 mutations and triple negative breast cancers.Preclinical mouse models for BRCA1-associated breast cancer.Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.Opportunities and hurdles in the treatment of BRCA1-related breast cancer.Genetic testing today.Assessing the role of platinum agents in aggressive breast cancers.BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Response Prediction Using Novel Optical Tomography Imaging: A Case Report.Breast cancer genetics: 20 years later.Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.Clinical implications for BRCA gene mutation in breast cancer.

P2860

Q26823419-856A6786-72CC-4A22-8526-1ABC5BDA86A0 Q30430808-66961BE4-7535-4F0F-A4E9-6BA0EBD377C6 Q30836057-CD11B10A-C0B7-4C4B-9525-4A0A36DC7EB1 Q33538053-358ADEBB-4DDA-4063-9BDD-25D58BBD607F Q33564013-29907AF0-9103-4811-84FB-57DBC5B698AE Q33710233-DEB90405-E359-493B-9ABD-BE885F46F3CC Q33900930-647460B4-D550-459D-A142-9DDD907759D2 Q33962070-EF9727BC-8C60-42F2-B7A5-4A5C9930AF75 Q34533964-B30F70F8-4001-4359-996A-B1AEC0F89439 Q34734477-E8000C76-5A6D-42BA-8EDA-26B32A509C45 Q34774884-ECBB56B3-33F3-4B46-9387-07D9841194E2 Q35200273-B292F31E-4AEE-4473-B103-1BC01FFD77EF Q35208929-8B827A74-38D1-4C7A-8356-19AD6F92A511 Q35976084-2CEAC00E-178E-4CA3-9BA0-AE996444BD1A Q36472233-83130BA8-E936-45FE-83AD-F8FC5FF2CA10 Q36879506-C5FED2DC-9189-4A86-B632-E79EC153B08F Q36920416-15AFD38B-B6F3-4F44-B3B7-5B64A50CB352 Q36924418-9B95A4B8-3D87-4385-A522-AF0BEC209EAD Q37128739-F92417B2-529C-47BA-9000-6D03118C6120 Q37177110-942952EE-CF5E-4850-AC75-6E8B1F2E9977 Q37349840-45A12153-2CFB-4828-9B0C-32CFFC20728F Q37379689-D5D6CA96-0B2E-4F7D-B77F-4E3BE11D26FB Q37396876-0BF48E82-44E7-457A-A03C-4DF89D973C85 Q37407985-843B879A-C800-41CA-8D85-8883EE134420 Q37424070-29EC1797-3B2D-4D28-9C87-3AA2D3AB3880 Q37477489-840AA40B-CCA7-4132-A96C-D6E305B6501F Q37630473-BEDDE150-274B-4939-93C2-C8C7136A72EE Q37677557-889305D8-C0DA-4D8D-8E7C-1AD169114D15 Q37687380-47792101-71BA-4BE2-B009-E1A236E8F929 Q38129725-4F1B780C-A5A5-47A7-A42B-3578CAABF2C5 Q38230196-46E9E129-B941-4C3B-9192-D86CABE7E64C Q38349378-B237C054-65B3-4C71-AAFF-EE93ECAE9201 Q38617840-160B7072-3316-48B3-ABA8-B664FDF8DFF2 Q38806371-28FB956F-4B49-4697-9505-422B477967DD Q38876050-532B2C1F-E64B-41B8-B4F4-DAF3DEED8AC4 Q41698953-5F86CFDF-4660-4F5B-9B6A-84191330AD11 Q43535015-188E7440-BF97-4135-9486-83ADA6A1F661 Q49829001-94EC6E8F-E7FA-4F7A-AA9A-61908311AB6D Q50604147-3A6F00E2-087F-445B-B446-AF9475CEB093 Q54580068-3D80941D-3976-467C-9CFC-ED9E4CABD78B

P2860

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

http://www.wikidata.org/entity/Q34579373

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

@ast

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

@en

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

@nl

type

label

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

@ast

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

@en

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

@nl

prefLabel

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

@ast

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

@en

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

@nl

P1433

Q34579373-6204CB48-FB8C-4B94-BC62-3D88048AAE19

P1476

Q34579373-4D2EF619-4BB3-42AA-8CF2-7AE3437D9C85

P2093

Q34579373-03E9A8D6-9A1D-4A8A-99C2-759085065AA6

Q34579373-1AD66827-0EC7-450B-9CC7-1E828DFA46D6

Q34579373-45D3D8BA-0243-4DEC-8A11-A1FF6D0C99EA

Q34579373-53640233-19AA-47D4-BF03-934B8058EC40

Q34579373-A3E8F719-B451-4731-BF23-960AA4A0B375

Q34579373-A51DCE40-DA1D-4E4A-9947-03B59CFE2B15

Q34579373-D3BFDD03-6561-424B-B1B6-099D3EED6932

Q34579373-E2D2457E-4F05-48E7-8C40-AE30074AB54F

Q34579373-E36CB764-1C68-46C6-AC3B-850BE0991F55

Q34579373-ED9F0DD7-A772-4789-B6E7-D9F8AB8BA9C1

P2860

Q34579373-94E8B2BB-27BA-42CB-BF1E-0502E48C8C23

Q34579373-D5ACC4F6-77EE-4DD2-9CE9-C57D6A870892

P2888

Q34579373-A6FE9965-CAEC-4C68-87C9-FE4B548E57D0

P304

Q34579373-913D6C78-E500-47A4-9FC0-8F36178DAA06

P31

Q34579373-D1765463-6178-451F-92BB-537AFC7271FD

P356

Q34579373-8F1E05A2-8E13-42E0-B9B7-20B465FF1F35

P407

Q34579373-F9299C85-EB96-43C8-8269-B0126D8770DF

P433

Q34579373-995691A0-7C71-46A7-A27D-F42338F7E6F7

P478

Q34579373-E2C97D18-EC13-4AAA-9F35-DEE3B7F566FC

P50

Q34579373-B25DE6A6-6121-4059-9338-788EAB1E156E

Q34579373-C8DC1B73-E4B0-4CF7-9536-0A1DFE9FE099

Q34579373-FAB1CF65-9B3E-4F52-8769-44CDCB7A6316

P577

Q34579373-13C8BCFA-7B82-45B5-980E-1ECEB3A241C7

P6179

Q34579373-7ACFFFE4-1E6C-43C7-A5FB-8BBA0346DC36

P698

Q34579373-F84C1FA2-CE55-424D-B7F1-A3AEDE08E372

P921

Q34579373-97531E35-39E5-44EF-A853-3B2F0650B34D

P356

S10549-007-9600-1

P1433

Breast Cancer Research and Treatment

P1476

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.

@en

P2093

E Grzybowska

http://www.w3.org/2001/XMLSchema#string

J Gronwald

http://www.w3.org/2001/XMLSchema#string

M Budryk

http://www.w3.org/2001/XMLSchema#string

M Siolek

http://www.w3.org/2001/XMLSchema#string

M Stawicka

http://www.w3.org/2001/XMLSchema#string

M Szwiec

http://www.w3.org/2001/XMLSchema#string

Polish Hereditary Breast Cancer Consortium

http://www.w3.org/2001/XMLSchema#string

R Wiśniowski

http://www.w3.org/2001/XMLSchema#string

T Huzarski

http://www.w3.org/2001/XMLSchema#string

T Mierzwa

http://www.w3.org/2001/XMLSchema#string

P2860

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

P2888

s10549-007-9600-1

P304

289-296

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-007-9600-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Steven A. Narod

P577

2007-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1020078075

http://www.w3.org/2001/XMLSchema#string

P698

17492376

http://www.w3.org/2001/XMLSchema#string

P921